biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT
WINDTREE THERAPEUTICS INC
WINDTREE THERAPEUTICS INC /DE/
Windtree Therapeutics is a biotech organization headquartered in Warrington, USA. It trades on NYSE under ticker WINT. Primary therapeutic focus areas include Respiratory Distress Syndrome, Cardiogenic Shock, Respiratory
Company details
- Status
- Public
- HQ
- 2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
- Founded
- 1992
- Employees
- 17
- Programs
- 15
- Drugs
- 9
- Patents
- 4
Lucinactant for Inhalation
Phase 2 · other · Respiratory Distress Syndrome, Newborn
Lucinactant for Inhalation for Respiratory Distress Syndrome, Newborn is a Phase 2 program (other) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).
Internal code 03-CL-1702
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- WINDTREE THERAPEUTICS INC /DE/
- Phase
- Phase 2
- Modality
- other
- Indication
- Respiratory Distress Syndrome, Newborn
- Status
- terminated
- Trials
- 1